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Abstract
Introduction and hypothesis Standardized measures enable
the comparison of outcomes across providers and treatments
giving valuable information for improving care quality and
efficacy. The aim of this project was to define a minimum
standard set of outcome measures and case-mix factors for
evaluating the care of patients with overactive bladder (OAB).
Methods The International Consortium for Health Outcomes
Measurement (ICHOM) convened an international working
group (WG) of leading clinicians and patients to engage in a
structured method for developing a core outcome set.
Consensus was determined by a modified Delphi process,
and discussions were supported by both literature review
and patient input.
Results The standard set measures outcomes of care for adults
seeking treatment for OAB, excluding residents of long-term
care facilities. The WG focused on treatment outcomes iden-
tified as most important key outcome domains to patients:
symptom burden and bother, physical functioning, emotional
health, impact of symptoms and treatment on quality of life,
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and success of treatment. Demographic information and case-
mix factors that may affect these outcomeswere also included.
Conclusions The standardized outcome set for evaluating
clinical care is appropriate for use by all health providers car-
ing for patients with OAB, regardless of specialty or geo-
graphic location, and provides key data for quality improve-
ment activities and research.
Keywords Overactive bladder . Outcomemeasures .
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Abbreviations
OAB Overactive bladder
ICHOM International Consortium for Health Outcomes
Measurement
WG Working group
VBHC Value-based health care
IUGA International Urogynecology Association
ICS International Continence Society
PTNS Posteroposterior percutaneous tibial nerve
stimulation
SNS Sacral neuromodulation
Introduction
Overactive bladder (OAB) is a symptom-based condition de-
fined as urinary urgency, with or without urgency inconti-
nence, usually accompanied by frequency and nocturia in
the absence of urinary tract infections or other obvious pathol-
ogy [1, 2]. It is a common condition that affects many indi-
viduals worldwide, with a prevalence estimated between 11.8
and 17%, with incidence increasing with increasing age. OAB
negatively impacts quality of life (QoL) and often results in
significant healthcare expenditures [3–5]. Treatments range
from conservative approaches, such as lifestyle intervention,
to pharmacological and surgical options. For many patients,
the process of seeking care involves frequent clinic appoint-
ments and multiple treatment approaches. A study of five
European countries and Canada found that the annual expen-
diture per patient for OAB ranged from 262 to 619 euros
(US$293–693). When indirect costs such as work absentee-
ism were included, the total cost for the estimated 25 million
people with OAB in the countries studied was 9.7 billion
euros [6]. Despite the significant cost of OAB management,
it is difficult to determine the most effective and efficient
treatment approaches because there are no standard outcome
metrics that allow comparison of outcomes and costs across
providers.
The discipline of value-based health care (VBHC) contains
the tools to support such a strategy [7]. VBHC defines Bvalue^
in healthcare as the ratio between the outcomes of care
delivered and the cost of achieving those outcomes. The
VBHC agenda focuses on the standardization of metrics to
promote comparison of outcomes and costs across providers
for identifying best practices for delivering high-value care
[8]. Standardized measures enable comparison of outcomes
across providers and treatments to improve care quality and
efficacy. Measures for evaluating care outcomes for OAB that
are most important to patients would be of great utility to
improve our understanding of which treatment options or
combinations offer greatest treatment value.
The International Consortium for Health Outcomes
Measurement (ICHOM) is a not-for-profit organization that
convenes international working groups of clinicians, re-
searchers, and patients to defineminimum sets of standardized
outcomes by medical condition with a focus on outcomes that
matter most to patients (www.ichom.org). Following such
development, ICHOM works to support implementation and
benchmarking of these standard sets to facilitate the adoption
of VBHC worldwide. The objective of this project was to
define a minimum standard set of outcomes for evaluating
OAB treatment. This set of outcome measures and case-mix
factors is designed to be appropriate for and easily implement-
ed by any clinician treating patients with OAB, regardless of
medical specialty, treatment given, or country of practice.
Methods
Working group
ICHOM convened an international working group (WG) of
clinicians, researchers, and patients who are experts in treating
OAB. Members were selected via review of the literature and
consultation with leaders in the field to provide global repre-
sentation across the key clinical disciplines involved, includ-
ing urology, urogynecology, geriatrics, and pelvic floor phys-
ical therapy (Table 1). The WG was led by a project team
composed of an ICHOM standardization director (SW), co-
leads (AW and IM), and research fellow (CF). All members
were physicians, three routinely treated patients with OAB
(AW, IM, CF), and all volunteered their time for the project.
The standardization director and research fellow were
employed by ICHOM. Funding for the project was provided
by the International Urogynecology Association (IUGA). To
better understand which outcome domains matter most to pa-
tients, the project team invited a patient representative to the
WG and held patient-group discussions.
Standard set scope
TheWG decided that the standard set would apply to outcomes
of care for all adult patients diagnosed with idiopathic OAB,
excluding residents of long-term care facilities, and
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unanimously agreed to define OAB according to the
International Continence Society (ICS)/IUGA definition.
Treatment approaches included first-line interventions such as
patient education and behavioral modification, bladder
retraining, pharmacological management, onabotulinumtoxinA
injection, posteroposterior percutaneous tibial nerve stimulation
(PTNS), sacral neuromodulation (SNS), and surgery.
Work process and decision making
The measure set was developed using a modified Delphi pro-
cess [9]. Between September 2015 and June 2016, the group
convened for eight teleconferences. Each addressed a specific
goal: establishing the scope of the measure set, defining the
patient population, selecting the appropriate outcomes and
case-mix domains, and defining the relevant metrics. For each
topic, the project team reviewed the existing literature and
current practices to develop proposals for discussion during
the teleconference. Detailed minutes of these discussions were
distributed to WG members, who then voted on each item
presented in the proposals via an online survey. Individual
proposal items required a 70%majority vote of survey respon-
dents to be included in the measure set. Survey items with
< 70% approval were either excluded from the set or revised
by the project team following comments and were again pre-
sented for discussion and voting at the next teleconference.
Selection of outcome and case-mix domains
Additional sources of information were sought to support the
selection of outcome domains. A systematic literature review
was performed to determine outcome domains currently used
to evaluate OAB. PubMed was searched with the terms
Boveractive bladder^ or Burinary bladder, overactive^ or
Blower urinary tract^ combined with Bpatient outcome
assessment^ or Boutcome assessment^ or Btreatment
outcome(s)^. Limits included full-text articles, humans, pub-
lication from 1 January /2000 to 31 December 2015, English
language (due to the language limits of the team leadership),
and data from earlier publications in the form of review arti-
cles and meta-analyses (complete description provided in
Supplementary Material 1).
Structured patient group discussions were conducted to
better understand what outcome domains mattered most to
patients. We aimed to balance this group by age, parity, phase
in the care cycle, clinical experience, and nationality. We
Table 1 Working group members by country and specialty, including organizations and specialty societies represented
Country Specialty Working group member Organization Specialty society
Australia Geriatric medicine George Szonyi Royal Prince Alfred Hospital CFA
Kate Moore School of Women’s and Children’s
Health, University of New South
Wales
ICS, CFA
Canada Geriatric medicine Adrian Wagg University of Alberta ICS ICI
The Netherlands Urology John Heesakkers Radboud University Medical Center EAU (AUA, ICS, SUFU)
New Zealand Biostatistics Peter Herbison Dunedin School of Medicine, Otago
University
Cochrane
Sweden Obstetrics and gynecology Ian Milsom Sahlgrenska Academy EUGA, IUGA, ICS ICI
United States Obstetrics and gynecology Caroline Foust-Wright Massachusetts General Hospital
Patient representative Anita Anderson
Physical therapy Jessica McKinney Marathon Physical Therapy & Sports
Medicine, LLC.
Urology Jennifer Anger University of California - Los Angeles SUFU
Urogynaecology Elizabeth Ann Gormley Dartmouth-Hitchcock Medical Center AUA, SUFU
Abraham Morse Guangzhou Women and Children’s
Medical Center
AUGS
Samantha Pulliam University of North Carolina at
Chapel Hill
AUGS
United Kingdom Pelvic floor medicine Philip Toozs-Hobson Birmingham Women’s NHS Foundation
Trust
IUGA
Outcomes research Nikki Cotterill Bristol Urological Institute ICI
Urogynaecology Linda Cardozo King’s College Hospital, National
Health Service (NHS)
EUGA (IUGA), BSUG,
ICS, ICI
CFA Continence Foundation of Australia, ICS International Continence Society, EAU European Association of Urology, AUA American Urological
Association, EUGA European Urogynaecology Assocation, IUGA International Urogynecological Association, SUFU Society of Urodynamics, Female
Pelvic Medicine & Urogenital Reconstruction, AUGSAmerican Urogynecologic Society, ICI International Consultation on Incontinence, BSUG British
Society of Urogynaecology
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recognize that this did not provide a fully representative sam-
ple of patients globally, however, our aim was to gather infor-
mation to guide our work, not to publish definitive results.
Specifically, patient groups were asked which outcomes were
most important to them, had the most effect on day-to-day life,
and if any domains were missing from those identified from
the literature review.
A comprehensive list of potential outcome domains was
identified from these sources and presented to the WG for
discussion. WG members were asked to score each potential
outcome on the Grades of Recommendation Assessment,
Development and Evaluation (GRADE) scale [10]. Outcome
domains scored as important (7–9) by at least 70% of respon-
dents were included in the set. Those scored as unimportant
(1–3) by at least 70% of respondents were excluded. Those
remaining were modified and represented for a second round
of voting. Domains meeting neither inclusion nor exclusion
criteria after a second round of voting were discussed again
and then presented for a final binary vote.
Once outcome domains were identified, each was defined.
All included domains were deemed appropriate for capture by
patient report. Relevant patient-reported outcome measures
(PROMs) were then identified from the literature and
reviewed for coverage, psychometric properties, validity, fea-
sibility to implement, and clinical interpretability, according to
International Society for Quality of Life Research (ISOQOL)
guidelines [11]. All PROMs proposed for discussion were
denoted as Grade A by the 5th International Consultation on
Incontinence (ICI) [12]. PROM sets that covered all outcome
domains of interest while minimizing question burden were
then presented to the WG for discussion and voting. A similar
process was followed to identify and define case-mix vari-
ables, and patient and procedural factors known to affect treat-
ment outcomes for inclusion in the standard set.
Patient validation surveys
To ensure robust patient input, we solicited feedback via an
anonymous online survey publicized via national continence-
related consumer organizations. The survey presented in lay
terms outcome domains voted for inclusion by the WG.
Respondents were asked to score those domains according to
their importance on the GRADE scale and given an opportunity
at the end of the survey to suggest any missing outcomes. The
resulting suggestions were presented to the WG to inform their
conclusions on the generalizability of the patient advisory group.
Open review process
To ensure transparency in the development process and allow
input from stakeholders outside the formal WG, a 4-week
open review period was held prior to the last WG teleconfer-
ence. Key stakeholders identified by the project team, IUGA
members, and individuals expressing interest in the measure
set via the ICHOM website received an overview of the set,
with links to the full detail reference guide and a feedback
survey. Results of this survey were presented to the WG for
discussion prior to set finalization.
Results
Outcome domains and measures
The literature search for outcome domains (Supplemental
Material 1) identified 585 articles. An additional 11 articles
were identified from other sources during the process. A title
and/or abstract review was used for further refinement. A total
of 184 articles were included for full-text review, and 39 were
included in the final qualitative synthesis. After reviewing re-
sults of the literature search and patient discussion groups, the
WG voted to include the following outcome domains in the
standard set: symptom frequency and burden, physical func-
tioning, interference with desired activities, emotional health,
social interactions, sexual functioning, treatment burden, and
overall satisfaction with the results of treatment. See Table 2
for a complete list of outcomes and outcome measures.
The International Consultation on Incontinence
Questionnaire Overactive Bladder Module (ICIQ-OAB) is an
eight-question instrument assessing the frequency of micturition,
nocturia, urgency, and incontinence and the amount of bother
caused by these symptoms [13, 14]. This PROM is validated for
assessing OAB, easy to complete, and free for use in clinical
practice and routine outcome measurement and was therefore
recommended by the WG.
The OAB-q, 26 questions of which form the ICIQ-OAB-q, is
a well-validated and commonly used instrument to assess the
effect of OAB on health-related QoL covering the domains of
coping, concern, sleep, and social interactions. The WG felt that
these domains mapped closely to the domains of physical func-
tioning, interference with desired activities, emotional health,
and social interactions that had been voted for inclusion in the
standard set [15]. However, at 33 questions long, it was consid-
ered by the WG to be too lengthy for use in standard clinical
practice. Instead, the 13-item short form of the OAB-Q (OAB-Q
SF) was recommended [16].
The WG voted to measure sexual function with the six-item
ICIQ Femala/Male Sexual Matters associated with Lower
Urinary Tract Symptoms (FLUTS/MLUTSsex) as applicable
according to gender [14, 17]. The Treatment Benefit Scale
(TBS), consisting of three questions assessing treatment efficacy,
treatment tolerability, and overall satisfactionwith treatment, was
included to assess the domains of treatment benefit, burden, and
satisfaction [18].
The resulting ICHOM standard set on OAB comprises 28
items.
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Patient validation surveys
Patient validation surveys revealed strong support for out-
comes selected by the WG. A total of 99 complete responses
to the survey was received from patients spanning a wide
range of ages and treatment approaches; 76% of participants
responded affirmatively to the question: BDo you feel this list
captures the outcomes that matter or have mattered the most to
you?^ No major deficits in domain coverage were identified.
Case-mix factors
Demographic and medical history data that might affect pa-
tient treatment outcomes were included in the standard set to
allow for risk-adjusted outcomes comparisons. See Table 3 for
a complete list of the case-mix factors and definitions.
The WG voted to include only age and sex as demographic
factors affecting OAB outcomes. Medications may have great-
er efficacy in patients < 65 years of age [19–25], and women
respond better to treatment than do men [21, 22, 26, 27].
Aspects of patients’ medical history that may affect treat-
ment outcomes or response to treatment included in the stan-
dard set were: body mass index (BMI), comorbid bowel con-
ditions, pelvic organ prolapse (POP), enlarged prostate,
history of prior pelvic surgeries, and diabetes or the metabolic
syndrome. Women with higher BMI may be more likely to
have urgency incontinence and increased symptom severity
[28, 29]. Studies suggest a link between OAB and irritable
bowel syndrome or other bowel conditions, although how this
affects treatment outcomes is less clear [30, 31]. The associa-
tion of OAB with anterior compartment prolapse resulted in
the consensus to include POP [32]. As prostate conditions can
increase storage symptoms, mimicking or worsening OAB
andmaking treatment less successful, this condition was voted
for inclusion in the case-mix factors [33, 34]. Histories of prior
pelvic surgery were included due to reports of new-onset
OAB following pelvic surgery [35]. Diabetes may exacerbate
OAB, which was also included [36–40]. The presence or ab-
sence of memory problems was also included; the WG felt
that, on balance, cognitive impairment could alter outcomes
despite the lack of supporting published evidence. Including a
measure that asks patients if they have been told by a doctor
that they have memory problems will allow further investiga-
tion into this issue.
Parity, mode of childbirth (vaginal versus Cesarean), and
menopausal status were ultimately excluded due to lack of
clear data on their relationship to OAB symptoms [41–50].
Current use of estrogens was included, as topical estrogen
Table 2 Outcome domains and
assessments in the standard set Category and outcome domain Agreement
a Outcome assessment Agreementa
OAB symptom severity and burden
Frequency of OAB symptoms 92 Tracked via ICIQ-OAB 83
Burden of OAB symptoms 100 Tracked via ICIQ-OAB 83
Health-related quality of life
Physical functioning 100 Assessed via the OAB-Q SF 85
Social impact 88 Assessed via the OAB-Q SF 85
Emotional health 100 Assessed via the OAB-Q SF 85
Interference with desired activities 75 Assessed via the OAB-Q SF 85
Sexual functioning 73 Assessed via the ICIQ-FLUTSsex
(women) or ICIQ-MLUTSsex
(men)
83
Treatment benefit and tolerance 82 My condition (urinary problems,
incontinence) has…(greatly
improved/improved/not
changed/worsened during
treatment). The tolerability
of my treatment for OAB is…
(inadequate, moderate, good,
excellent).
77
Overall satisfaction with treatment 100 My overall satisfaction is…
(extremely satisfied/very
satisfied/satisfied/not satisfied
with the treatment).
77
ICIQ International Consultation on Incontinence Questionnaire, OAB overactive bladder, OAB-Q SF symptom
bother and health-related quality of life (HRQL) questionnaire, FLUTS Female Sexual Matters associated with
Lower Urinary Tract Symptoms, MLUTSsex Male Sexual Matters associated with Lower Urinary Tract
Symptoms
a Percentage agreement among survey respondents (voting IN)
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has been shown to ameliorate OAB symptoms and systemic
estrogen to be associated with worsening [51, 52].
Current OAB treatment is included in the standard set as an
explanatory variable. By tracking patients’ treatment in parallel
with their outcomes and medical profiles will help identify par-
ticularly effective treatments for different patient populations.
The WG opted to collect all case-mix factors via patient
reports to simplify implementation of the standard set. As
all outcomes in the set are patient reported, all data are cap-
tured from a single source, streamlining data collection
within the clinic and eliminating the need to integrate
PROM data collection in electronic medical records
(EMRs) or to align patient-reported and clinical data follow-
ing collection.
Initial data collection and follow up
The standard set is designed for data collection to begin at the
time of diagnosis, with follow-up at intervals defined by the
treating clinician and to end at the time of patient-reported
treatment success or loss to follow-up (Fig. 1). Baseline mea-
sures include both case-mix factors and all PROMs. Although
studies suggest that baseline severity does not affect response
to treatment, it may affect patient motivation to adhere to
treatment and tolerate side effects [53, 54]. All PROMs are
collected at the time of diagnosis to calculate the effect of
treatment over time.
Follow-up measures include all PROMs and explanatory
variables. The WG recommended that follow-up surveys be
completed as deemed appropriate by the treating clinician.
Follow-up ends at patient-defined success, i.e., positive re-
sponses to the TBS questions and/or no further follow-up for
6 months. Subsequent presentations for treatment after
6 months are recorded as new episodes of care for the same
patient. Treatment outcome is then defined as the difference in
PROMs at patient-reported treatment success or the last avail-
able follow-up survey and baseline adjusted by relevant case-
mix factors.
Discussion
The ICHOM OAB WG aimed to develop a comprehensive,
minimally burdensome, patient-centered, standard set of
Table 3 Case-mix variable domains and definitions included in the standard set
Category and case-mix factor domain Agreementa Case-mix factor definition Agreementa
Demographic factors
Age 100 Year of birth 93
Sex 100 Patient sex 86
Baseline clinical factors
BMI 85 How much do you weigh? (Weight in kgs or lbs). How tall are you?
(Height in cm or inches).
100
Comorbid bowel condition 71 Have you been told by your doctor or care provider that you have any
of the following? Tick all that apply. 0 = None, 2 = Irritable bowel
syndrome, 3 = Inflammatory bower disease (Crohn’s, ulcerative colitis).
86
Diabetes 77 Have you been told by your doctor or care provider that you have any
of the following? Tick all that apply. 1 = Diabetes.
86
Cognitive impairment 86 Have you been told by your doctor or care provider that you have any
of the following? Tick all that apply. 4 = A problem with your memory.
86
Coexisting pelvic organ prolapse 77 Do you have a feeling of a lump or Bsomething coming down^ or the need
to manually replace a prolapse in order to empty your bladder?
93
Coexisting stress incontinence 71 Do you leak urine with physical activity, coughing, laughing, or sneezing
or have you been told by a doctor that you have stress incontinence?
92
BPH or prostatitis 93 Have you been told by a doctor that you have a problem with your prostate?
Tick all that apply. 0 = No, 1 = Enlarged prostate or benign prostatic
hyperplasia (BHP), 3 = Prostatitis.
85
Current use of estrogens 92 Are you currently taking estrogens or hormone replacement therapy by
mouth, a patch or cream on the skin, or as a suppository?
92
History of pelvic surgery 92 Have you had surgery to your pelvis? Please indicate what kind.
Female response options: 0 = No; 1 = Yes, surgery for stress urinary
incontinence; 2 = Yes, prolapse surgery; 3 = Yes, surgery to the rectum
or bowel; 4 = Yes, hysterectomy; 5 = Yes, other surgery.
Male response options: 0 = No; 1 = Yes, surgery to the rectum or bowel;
2 = Yes, prostate surgery.
92
Current OAB treatments 100 What are you currently using to treat your OAB symptoms? 100
BMI body mass index, BPH benign prostatic hyperplasia, OAB overactive bladder
a Percentage agreement among survey respondents (voting IN)
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outcome measures for evaluating the care of patients with
OAB for use in routine clinical care. This led to the devel-
opment of an outcome set that is efficient to collect and
provides clinicians with a holistic view of treatment out-
comes. This was accomplished by convening and guiding a
WG of experts representing a broad range of stakeholders
through a structured process, grounded in literature and
expert opinion, to achieve consensus. Patients were includ-
ed in the process to better determine what outcome domains
mattered most to them. In addition, the WG limited its
recommendation to measures that are free for use and
broadly translated, allowing for set’s adoption around the
globe. All variables in the set are collected by patient re-
port, and follow-up intervals are left to the clinician’s dis-
cretion, as protocols may differ across specialties/countries.
This allows for flexible data collection from the patient
upon arrival at the clinic or remotely via mailed survey,
patient portal, secure email, or app. It is important to note
that the patient-reported case-mix factors were developed
by the WG and therefore require further validation. To fa-
cilitate this validation and pilot the standard set as a whole,
ICHOM supports members of the WG and other interested
parties to implement the set and design validation studies.
This work is overseen by a six-member steering committee,
elected from the initial WG, that governs changes to the
standard set over time.
The standard set was developed to have the lowest possible
burden on patients and providers while collecting necessary
data for comparison of outcomes. Thus, some measures
discussed by the WG were not included in the final set: for
example, a bladder diary (voiding diary) was not included to
decrease the burden on patients of data collection. It was felt
that tracking changes in symptom frequency and burden via
the ICIQ-OAB adequately captured symptom severity and
frequency.
In conclusion, this standard measure set provides mean-
ingful, comparable, and easy-to-interpret measures for
evaluating the care of patients with OAB. The inclusion
of case-mix factors enables global comparisons of treat-
ment outcomes across population groups. In time, it is
anticipated/proposed that knowledge from these compari-
sons will encourage and empower providers to improve
care and allow patients, providers, and payers to make in-
formed decisions about their healthcare spending and treat-
ment options.
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Int Urogynecol J (2017) 28:1785–1793 1791
Sources of funding This work was developed by the International
Consortium for Health Outcomes Measurement, a nonprofit organization
based in Cambridge, Massachusetts. Sponsorship for this work was pro-
vided by the International Urogynecological Association (IUGA) through
an unrestricted grant. IUGA had no control over the formation of the
expert panel, the recommendations, or the submitted publication.
Compliance with ethical standards
Conflict of interest Dr. Stowell, Dr. Wissig, Dr. Foust-Wright and Ms.
Olson were paid by ICHOM to support the development of this work. Dr.
Gormley holds position of leadership at the American Urologic
Association. Dr. Milsom has received paid travel expenses or honoraria
from Allergan, Astellas, Pfizer, and SCA. Dr. Cardozo has received
funding for research or lecturing for Astellas and Pfizer and for research
consultancy and/or advisory work for Allergan, Astellas, BMR, Ferring,
Pfizer & Syner-Med. Dr. Cotterill has accepted payment for research from
Astellas Pharma Europe BVand for consulting services from Procter and
Gamble. Dr. Anger declares that she is an investigator for Boston
Scientific Corporation and Astellas. Dr. Toozs-Hobson has received paid
travel expenses or honoraria from Astellas, SEP, Pierre Fabre, Allergan,
and Boston Scientific Corporation. Dr. Heesakkers has accepted paid
travel expenses or honoraria or payment for research from Astellas,
Allergan, Pierre Fabre, and Bluewind. No other conflicts of interest are
reported.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Abrams P, Cardozo L, Fall M, et al. The standardisation of termi-
nology in lower urinary tract function: Report from the
Standardisation Subcommittee of the International Continence
Society. Joint publication: Neurourol Urodyn. 2002;21(2):167–
178, Urology. 2003;61:37–49.
2. Haylen BT, de Ridder D, Freeman RM, et al. An international
Urogynecological association (IUGA)/international continence so-
ciety (ICS) joint report on the terminology for female pelvic floor
dysfunction. Neurourol Urodyn. 2010;29(1):4–20. https://doi.org/
10.1002/nau.20798.
3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of
urinary incontinence, overactive bladder, and other lower urinary
tract symptoms in five countries: results of the EPIC study. Eur
Urol. 2006;50:1306–14.
4. Milsom I, Coyne KS, Nicholson S, et al. Global prevalence and
economic burden of urgency urinary incontinence: a systematic
review. Eur Urol. 2014;65(1):79–95. https://doi.org/10.1016/j.
eururo.2013.08.031.
5. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and
burden of overactive bladder in the United States. World J Urol.
2003;20:327–36.
6. Irwin DE, Mungapen L, Milsom I, et al. The economic impact of
overactive bladder syndrome in six western countries. BJU Int.
2009;103:202–9.
7. Porter ME, Lee TH. The strategy that will fix health care. Harvard
Bus Rev. 2013;91:50–70.
8. Porter ME. What is value in health care? N Engl J Med. 2010;363:
2477–81. https://doi.org/10.1056/NEJMp1011024.
9. Pill J. The Delphi method: substance, context, a critique and an
annotated bibliography. Socio Econ Plan Sci. 1971;5(1):57–71.
https://doi.org/10.1016/0038-0121(71)90041-3.
10. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2.
Framing the question and deciding on important outcomes. J Clin
Epidemiol. 2011;64(4):395–400. https://doi.org/10.1016/j.jclinepi.
2010.09.012.
11. Cleary PD, Meterko M, Wright SM, Zaslavsky AM. Are compari-
sons of patient experience across hospitals fair? A study in veterans
health administration hospitals. Med Care. 2014;52(7):619–25.
https://doi.org/10.1161/HYPERTENSIONAHA.113.02854.
Impact.
12. 5th International Consultation on Incontinence. Editors Abrams,
Cardozo, Kouhry and Wein. Health Publications Ltd, Paris 2013.
13. Donovan J, Abrams P, Peters T, et al. The ICS-'BPH' study: the
psychometric validity and reliability of the ICSmale questionnaire.
BJU. 1996;77:554–62.
14. Jackson S, Donovan J, Brookes S, et al. The Bristol female lower
urinary tract symptoms questionnaire: development and psycho-
metric testing. BJU. 1996;77:805–12.
15. Khullar V. Patient-reported outcomes and different approaches to
urinary parameters in overactive bladder: what should we measure?
Int Urogynecol J. 2012;23:179–92.
16. Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive blad-
der symptom and health-related quality of life short-form: valida-
tion of the OAB-q SF. Neurourol Urodyn. 2015;34(3):255–63.
17. Frankel S, Donovan J, Peters T, et al. Sexual dysfunction in men
with lower urinary tract symptoms. J Clin Epidemiol. 1998;51(8):
677–85.
18. Colman S, Chapple C, Nitti V, et al. Validation of treatment benefit
scale for assessing subjective outcomes in treating overactive blad-
der. Female Urology. 2008;72(4):803–7. https://doi.org/10.1016/j.
urology.2008.05.033.
19. Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-
release oxybutynin and tolterodine for treating overactive bladder in
women. Int Urogynecol J Pelvic Floor Dysfunct. 2004;15(4):243–8.
20. Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose
titration with darifenacin, an M3-selective receptor antagonist. BJU
Int. 2005;95(4):580–6.
21. Layton D, Pearce G, Shakir S. Safety profile of tolterodine as used
in general practice in England. Drug Saf. 2001;24(9):703–13.
22. Michel MC, Schneider T, Krege S, Goepel M. Does gender or age
affect the efficacy and safety of tolterodine? J Urol. 2002;168(3):
1027–31.
23. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolera-
bility of extended-release once-daily tolterodine treatment for over-
active bladder in older versus younger patients. J Am Geriatr Soc.
2002;50(5):799–807.
24. Hill S, Elhilali M, Millard R, et al. Long-term darifenacin treatment
for overactive bladder in patients aged 65 years and older. CurrMed
Res Opin. 2007;23(11):2697–704.
25. Elinoff V, Bavendam T, Glasser DB, et al. Symptom specific effi-
cacy of tolterodine extended release in patients with overactive
bladder: the IMPACT trial. Int J Clin Pract. 2006;60(6):745–51.
26. Freeman R, Hill S, Millard R, et al. Reduced perception of urgency
in treating overactive bladder with extended-release tolterodine.
Obstet Gynecol. 2003;102(3):605–11.
27. Zinner N, GittelmanM, Harris R, et al. Trospium chloride improves
overactive bladder symptoms: a multicenter phase III trial. J Urol.
2004;171(6 Pt 1):2311–5.
28. Swift S, Garely A, Dimpfl T, Payne C. A new once-daily formula-
tion of tolterodine provides superior efficacy and is well tolerated in
women with overactive bladder. Int Urogynecol J Pelvic Floor
Dysfunct. 2003;14(1):50–5.
29. Khullar V, Sexton CC, Thompson CL, et al. The relationship be-
tween BMI and urinary incontinence subgroups: results from
1792 Int Urogynecol J (2017) 28:1785–1793
EpiLUTS. Neurourol Urodyn. 2014;33(4):392–9. https://doi.org/
10.1002/nau.22428.
30. Matsumoto S, Hashizume K, Wada N, et al. Relationship between
overactive bladder and irritable bowel syndrome: a large-scale in-
ternet survey in Japan using the overactive bladder symptom score
and Rome III criteria. BJU Int. 2013;111(4):647–52.
31. Bulchandani S, Toozs-Hobson P, Parsons M, et al. Effect of anti-
cholinergics on the overactive bladder and bowel domain of the
electronic personal assessment questionnaire (ePAQ). Int
Urogynecol J. 2015;26(4):533–7.
32. Salvatore S, Serati M, Ghezzi F, et al. Efficacy of tolterodine in
women with detrusor overactivity and anterior vaginal wall pro-
lapse: is it the same? BJOG. 2007;114(11):1436–8.
33. Eckhardt MD, van Venrooij GE, Boon TA. Symptoms and quality
of life versus age, prostate volume, and urodynamic parameters in
565 strictly selected men with lower urinary tract symptoms sug-
gestive of benign prostatic hyperplasia. Urol. 2001;57(4):695–700.
34. Seki N, Yuki K, Takei M, et al. Analysis of the prognostic factors
for overactive bladder symptoms following surgical treatment in
patients with benign prostatic obstruction. Neurourol Urodyn.
2009;28(3):197–201.
35. DeBoer TA,Kluivers KB,WithagenMI, et al. Predictive factors for
overactive bladder symptoms after pelvic organ prolapse surgery.
Int Urogynecol J. 2010;21(9):1143–9.
36. Chui A, HuangM,Wang C, Kuo H. Higher glycosylated hemoglo-
bin levels increase the risk of overactive bladder syndrome in pa-
tients with type 2 diabetes mellitus. Int J of Urology. 2012;19(11):
995–1001.
37. Tubaro A. Defining overactive bladder: epidemiology and burden
of disease. Urology. 2004;64:2–6.
38. Bunn F, Kirby M, Pinkney E, et al. Is there a link between overac-
tive bladder and the metabolic syndrome in women? A systematic
review of observational studies. Int J Clin Pract. 2015;69(2):199–
217.
39. Tai HC, Chung SD, Ho CH, et al. Metabolic syndrome components
worsen lower urinary tract symptoms in women with type 2 diabe-
tes. J Clin Endocrinol Metab. 2010;95(3):1143–50.
40. Karoli R, Bhat S, Fatima J, Priya S. A study of bladder dysfunction
in women wit type 2 diabetes mellitus. Indian J Endocrinol Metab.
2014;18(4):552–7.
41. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive
bladder, incontinence and other lower urinary tract symptoms on
quality of life, work productivity, sexuality and emotional well-
being in men and women: results from the EPIC study. BJU Int.
2008;101:1388–95.
42. Bradley CS, Kennedy CM, Nygaard IE. Pelvic floor symptoms and
lifestyle factors in older women. JWomen's Health. 2005;14:128–36.
43. Parazinni F, Chiaffarino F, Lavezzari M, et al. Risk factors for
stress, urge or mixed urinary incontinence in Italy. BJOG.
2003;110:927–33.
44. Tikkanen KA, Auvinen A, Tiitinen A, et al. Reproductive factors
associated with nocturia and urinary urgency in women: a
population-based study in Finland. Am J Obstet Gynecol.
2008;199(2):153.e1–12.
45. Lawrence JM, Lukacz ES, Nager CW, et al. Prevalence and co-
occurrence of pelvic floor disorders in community-dwelling wom-
en. Obstet Gynecol. 2008;111(3):678–85.
46. Chuang FC, Kuo HC. Prevalence of lower urinary tract symptoms
in indigenous and non-indigenous women in eastern Taiwan. J
Formos Med Assoc. 2010;109(3):228–36.
47. Alling Möller L, Lose G, Jørgensen T. Risk factors for lower uri-
nary tract symptoms in women 40 to 60 years of age. Obstet
Gynecol. 2000;96:446–51.
48. Handa VL, Harvey L, Fox HE, Kjerulff KH. Parity and route of
delivery: does cesarean delivery reduce bladder symptoms later in
life? Am J Obstet Gynecol. 2004;191(2):463–9.
49. Zhang W, Song Y, He X, et al. Prevalence and risk factors of over-
active bladder syndrome in Fuzhou Chinese women. Neurourol
Urodyn. 2006;25(7):717–21.
50. Robinson D, Cardozo L, Milsom I, et al. Oestrogens and overactive
bladder. Neurourol Urodyn. 2014;33(7):1086–91.
51. Tseng LH, Wang AC, Chang YL, et al. Randomized comparison of
tolterodine with vaginal estrogen cream versus tolterodine alone for
the treating postmenopausal women with overactive bladder syn-
drome. Neurourol Urodyn. 2009;28(1):47–51.
52. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A.
Oestrogen therapy for urinary incontinence in post-menopausal
women. The Cochrane database of systematic reviews. 2012;10:
Cd001405.
53. Garely AD, Lucente V, Vapnek J, Smith N. Solifenacin for overac-
tive bladder with incontinence: symptom bother and health-related
quality of life outcomes. Ann Pharmacother. 2007;41(3):391–8.
54. Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic
therapy for overactive bladder with varying degrees of incontinence
severity. J Urol. 2004;171(2 Pt 1):752–6.
Int Urogynecol J (2017) 28:1785–1793 1793
